| 货号 | 17425-5mg |
| 描述 | Lipoprotein lipase (LPL) mediates the hydrolysis of triglycerides in circulating very low density lipoproteins and chylomicrons.1,2 NO-1886 is an LPL activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle.3 This coincides with an elevation in post-heparin plasma LPL activity and LPL mass in rats.3,4 NO-1886 decreases plasma triglyceride concentration and increases plasma high-density lipoprotein cholesterol, resulting in inhibited development of atherosclerotic lesions in coronary arteries and aortas of rats and rabbits.3,4 |
| 别名 | Ibrolipim;Lipoprotein Lipase Activator;LPL Activator;OPF 009; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Kim, M.S.,Wang, Y. and Rodrigues, B. Lipoprotein lipase mediated fatty acid delivery and its impact in diabetic cardiomyopathy. Biochimica et Biophysica Acta 1821(5), 800-808 (2011). 2.Olivecrona, G. and Olivecrona, T. Triglyceride lipases and atherosclerosis. Current Opinion in Lipidology 21, 409-415 (2010). 3.Yin, W. and Tsutsumi, K. Lipoprotein lipase activator NO-1886. Cardiovascular Drug Reviews 21(2), 133-142 (2003). 4.Tsutsumi, K.,Inoue, Y.,Shima, A., et al. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. Journal of Clinical Investigation 92(1), 411-417 (1993). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 451.3 |
| 分子式 | C19H20BrN2O4P |
| CAS号 | 133208-93-2 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |